What development phase is Slentrol in?

Slentrol is FDA-approved (marketed).

What is the generic name of Slentrol?

DIRLOTAPIDE is the generic (nonproprietary) name of Slentrol.

Last reviewed 2026-04-20 · How we verify

Slentrol (DIRLOTAPIDE)

FDA-approved active Small molecule Quality 5/100

Slentrol (DIRLOTAPIDE) is a small molecule modality targeting the microsomal triglyceride transfer protein large subunit. Its exact drug class is unknown, and its commercial status is unclear. Slentrol is not FDA-approved for any indications, and its pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to determine its potential therapeutic applications and safety profile. As a result, Slentrol is not yet available as a generic medication.

At a glance

Generic name	DIRLOTAPIDE
Target	Microsomal triglyceride transfer protein large subunit
Modality	Small molecule
Therapeutic area	Metabolic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Slentrol CI brief — competitive landscape report
Slentrol updates RSS · CI watch RSS